Peptide news
New studies, FDA announcements and science and industry reporting on the peptides we track, collected every morning from PubMed, the FDA and established science and health publishers.
- NewsMedical XpressIntensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors
- NewsBioPharma DiveAstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
- NewsMedical XpressStopping Ozempic may be bad for your health
- NewsMedical XpressGLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments
- NewsMedical XpressEngineered protein that cuts Alzheimer's-linked brain deposits opens potential therapeutic avenue
- NewsMedical XpressAustralia is set to get a Wegovy pill. How does it compare with weight‑loss injections?
- NewsMedical XpressAbout half of drinkers on GLP-1s say they imbibed less
- NewsMedical XpressAnorexia and bulimia cases projected to reach nearly 22 million by 2050
- NewsMedical XpressGLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention medication
- NewsMedical XpressGLP-1 drugs may help patients shed regained weight after bariatric surgery
- NewsMedical XpressRFK Jr. eases access to unproven peptides despite opposition from FDA scientists
- NewsMedical XpressPeptide users don't think of themselves as injecting drug users. Five safety basics injectors need to know
- NewsMedical XpressAre GLP-1s practical and safe for adolescents with obesity?
- NewsMedical XpressOnce-daily oral icotrokinra outperforms placebo in ulcerative colitis
- NewsMedical XpressAAO: Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure
Headlines link to the original publisher; we don't write or edit these stories. Research summaries are for education only and are not medical advice. For plain-English background on each peptide, see our research guides.
Free weekly email
Get The Peptide Audit Weekly
Every Monday: the week's price drops and restocks, new third-party lab results, and a plain-English research guide with the latest studies. No spam — unsubscribe anytime.